• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc. (Amendment)

    2/14/23 4:45:49 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MIST alert in real time by email
    SC 13G/A 1 ss1758602_sc13ga.htm AMENDMENT NO. 1
     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

    (Amendment No. 2)*

         

    Under the Securities Exchange Act of 1934

     

         

     

    Milestone Pharmaceuticals, Inc.
    (Name of Issuer)

     

     

    Common Shares, no par value per share
    (Title of Class of Securities)

     

     

    59935V107
    (CUSIP Number)

     

     

    December 31, 2022
    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

    x Rule 13d-1(b)

    o Rule 13d-1(c)

    o Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
       

     

    CUSIP No. 59935V107  SCHEDULE 13G Page 2 of 6 Pages

     

             
    1

    NAME OF REPORTING PERSONS

     

    OrbiMed Capital LLC

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) o

    (b) o

     
    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

    NUMBER OF

    SHARES

    BENEFICIALLY

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    0

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    0

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    0

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    o
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    0%

    12

    TYPE OF REPORTING PERSON

     

    IA

     

     

     

     

       

     

    CUSIP No.  59935V107  SCHEDULE 13G Page 3 of 6 Pages

     

    Item 1.   (a) Name of Issuer:

    Milestone Pharmaceuticals, Inc.

        (b) Address of Issuer’s Principal Executive Offices:

    1111 Dr. Frederik-Philips Boulevard

    Suite 420

    Montréal, Québec, Canada H4M 2X6

    Item 2.   (a) Name of Person Filing:

    OrbiMed Capital LLC

        (b) Address of Principal Business Office:

    601 Lexington Avenue, 54th Floor

    New York, NY 10022

        (c) Citizenship:

    Please refer to Item 4 on the cover page for the Reporting Person.

        (d) Title of Class of Securities:

    Common Shares, no par value per share

        (e) CUSIP No.:

    59935V107

     

     

     

     

     

     

     

     

     

     

       

     

    CUSIP No. 59935V107  SCHEDULE 13G Page 4 of 6 Pages

     

     

    Item 3.      

    OrbiMed Capital LLC (“Capital”) is an investment advisor in accordance with ss.240.13d-1(b)(1)(ii)(E).

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

       

     

    CUSIP No. 59935V107  SCHEDULE 13G Page 5 of 6 Pages

     

     

    Item 4. Ownership:

    Information with respect to the Reporting Person’s ownership as of December 31, 2021 is incorporated by reference to items (5) - (9) and (11) of the cover page for the Reporting Person.

    Item 5. Ownership of Five Percent or Less of a Class.

    If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☒.

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.

    Not Applicable.

    Item 7. Identification and Classification of the Subsidiary which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

    Not Applicable.

    Item 8. Identification and Classification of Members of the Group.

    Not Applicable.

    Item 9. Notice of Dissolution of Group. 

    Not Applicable.

    Item 10. Certification.

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

     

     

     

     

     

     

       

     

    CUSIP No. 59935V107  SCHEDULE 13G Page 6 of 6 Pages

     

     

    SIGNATURES

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

     

           
      OrbiMed Capital LLC
           
      By:  /s/ Carl L. Gordon
        Name:  Carl L. Gordon
        Title:  Member

     

     

     

     

     

     

     

     

     

     

     

       
    Get the next $MIST alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $MIST

    DatePrice TargetRatingAnalyst
    12/15/2025$8.00Hold → Buy
    TD Cowen
    9/11/2025$4.00Overweight
    Wells Fargo
    6/5/2025$5.00Buy
    H.C. Wainwright
    8/22/2024$9.00Buy
    Rodman & Renshaw
    6/20/2023$8.00 → $4.00Buy → Hold
    Jefferies
    4/22/2022$8.00 → $10.00Neutral → Overweight
    Piper Sandler
    More analyst ratings

    $MIST
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Amendment: SEC Form 4 filed by Chief Medical Officer Bharucha David

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:19 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by President and CEO Oliveto Joseph

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:21 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form 4 filed by Chief Commercial Officer Muller Lorenz

    4/A - Milestone Pharmaceuticals Inc. (0001408443) (Issuer)

    2/5/26 4:30:13 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Milestone Pharmaceuticals upgraded by TD Cowen with a new price target

    TD Cowen upgraded Milestone Pharmaceuticals from Hold to Buy and set a new price target of $8.00

    12/15/25 10:09:22 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wells Fargo initiated coverage on Milestone Pharmaceuticals with a new price target

    Wells Fargo initiated coverage of Milestone Pharmaceuticals with a rating of Overweight and set a new price target of $4.00

    9/11/25 8:45:07 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright resumed coverage on Milestone Pharmaceuticals with a new price target

    H.C. Wainwright resumed coverage of Milestone Pharmaceuticals with a rating of Buy and set a new price target of $5.00

    6/5/25 7:34:51 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

    FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placeboCARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1Company to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE

    3/20/26 7:12:14 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals to Present Data on CARDAMYST™ (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

    MONTREAL and CHARLOTTE, N.C., March 16, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that a moderated poster presentation titled "Minimal Blood Pressure Effects of Intranasal Etripamil in Trials for Paroxysmal Supraventricular Tachycardia (PSVT)" will be featured at the 2026 American College of Cardiology Annual Scientific Session (ACC.26), March 28-30th in New Orleans, La. An Expert Theater will also be conducted at ACC.26, providing a deeper look at this new treatment option for adults with symptomatic PSVT. "Although potential h

    3/16/26 8:13:15 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

    MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13759195Webcast link:click here Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made acti

    3/12/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    SEC Filings

    View All

    Milestone Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

    3/20/26 7:25:07 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Milestone Pharmaceuticals Inc.

    10-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

    3/20/26 7:07:41 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - Milestone Pharmaceuticals Inc. (0001408443) (Filer)

    1/26/26 9:27:42 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    Financials

    Live finance-specific insights

    View All

    Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST™ (etripamil) Nasal Spray for the Treatment of PSVT

    FDA approval of CARDAMYST represents first new option in 30 years for the more than two million patients with PSVTParticipants using CARDAMYST in clinical studies were 2x more likely to convert symptomatic PSVT to sinus rhythm and did so more than 3x faster compared with placeboCARDAMYST launch execution on track with positive initial engagement in the product from healthcare providers and payers $200 million pro forma cash supports strong launch and operating runway into late 2027; includes $106 million of cash at year-end and net proceeds from subsequent financing activities1Company to host investor call and webcast at 8:30am ET today MONTREAL and CHARLOTTE, N.C., March 20, 2026 (GLOBE

    3/20/26 7:12:14 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals to Announce Fourth Quarter and Full-Year 2025 Financial Results on March 20, 2026

    MONTREAL and CHARLOTTE, N.C., March 12, 2026 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST) today announced that it will report fourth quarter and full-year 2025 results and provide a business update on Friday, March 20, 2026, before the market opens. The announcement will be followed by a conference call and webcast for investors at 8:30am ET. Conference Details: Conference Dial-in:1-877-407-0792International Dial-in:1-201-689-8263Conference ID:13759195Webcast link:click here Call me™: Participants can use Guest dial-in numbers above and be answered by an operator OR click the Call me™ link for instant telephone access to the event. The Call me™ link will be made acti

    3/12/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (PSVT)

    First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly resolve episodes of PSVT and restore sinus rhythmFDA approval in PSVT enables development of AFib-RVR under sNDA pathwayMilestone well-capitalized to launch and commercialize CARDAMYST with existing capital and royalty financingConference call and webcast December 15, 8:00 a.m. ET MONTREAL and CHARLOTTE, N.C., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc.  (NASDAQ:MIST) today announced that the U.S. Food and Drug Administration (FDA) approved its first commercial product, CARDAMYST™ (etripamil) nasal spray, a prescription medication for the conver

    12/12/25 8:00:00 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $MIST
    Leadership Updates

    Live Leadership Updates

    View All

    Milestone Pharmaceuticals Appoints David Sandoval as General Counsel and Chief Compliance Officer

    MONTREAL and CHARLOTTE, N.C., Feb. 10, 2026 (GLOBE NEWSWIRE) -- Milestone Pharmaceuticals Inc. (NASDAQ:MIST) today announced the appointment of David Sandoval as General Counsel and Chief Compliance Officer. Mr. Sandoval's appointment comes as Milestone launches CARDAMYST™ (etripamil) nasal spray, the first and only approved self-administered treatment for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. CARDAMYST was approved by the U.S. Food and Drug Administration (FDA) on December 12, 2025. He will serve as a member of Milestone's executive leadership team and will provide business-focused legal counsel across all

    2/10/26 8:00:00 AM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

    4/10/25 8:30:00 AM ET
    $ACOG
    $CBAY
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Milestone Pharmaceuticals Appoints Industry Veteran Joseph Papa to its Board of Directors

    MONTREAL and CHARLOTTE, N.C., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Milestone® Pharmaceuticals Inc. (NASDAQ:MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the appointment of Joseph Papa to its Board of Directors ("Board"), effective September 3, 2024. Mr. Papa is a renowned pharmaceutical and healthcare leader, with more than 35 years of experience navigating companies through periods of rapid growth, transformation, and strategic M&A transactions, including as former Chairman and CEO of Bausch + Lomb, Bausch Health and Perrigo and as a director of SparingVision and Candel Therapeutics. He brings bro

    9/4/24 8:00:00 AM ET
    $CADL
    $EBS
    $MIST
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $MIST
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc.

    SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

    10/29/24 4:30:20 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Milestone Pharmaceuticals Inc.

    SC 13D/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

    7/16/24 6:06:24 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Milestone Pharmaceuticals Inc. (Amendment)

    SC 13G/A - Milestone Pharmaceuticals Inc. (0001408443) (Subject)

    2/14/24 8:56:08 PM ET
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care